Geertsma R - Search Results

1

Future perspectives for advancing regulatory science of nanotechnology-enabled health products.

Halamoda-Kenzaoui B, Geertsma R, Pouw J, Prina-Mello A, Carrer M, Roesslein M, Sips A, Weltring KM, Spring K, Bremer-Hoffmann S. Halamoda-Kenzaoui B, et al. Among authors: geertsma r. Drug Deliv Transl Res. 2022 Sep;12(9):2145-2156. doi: 10.1007/s13346-022-01165-y. Epub 2022 Jun 12. Drug Deliv Transl Res. 2022. PMID: 35691982 Free PMC article.

2

Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.

De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. De Jong WH, et al. Biomaterials. 2008 Apr;29(12):1912-9. doi: 10.1016/j.biomaterials.2007.12.037. Epub 2008 Feb 1. Biomaterials. 2008. PMID: 18242692

3

A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS.

Zabeo A, Rosada F, Pizzol L, Caputo F, Borgos SE, Parot J, Geertsma RE, Pouw JJ, Vandebriel RJ, Moreno OI, Hristozov D. Zabeo A, et al. Among authors: geertsma re. Drug Deliv Transl Res. 2022 Sep;12(9):2101-2113. doi: 10.1007/s13346-022-01145-2. Epub 2022 May 10. Drug Deliv Transl Res. 2022. PMID: 35538190 Free PMC article.

4

Regulatory safety evaluation of nanomedical products: key issues to refine.

De Jong WH, Geertsma RE, Borchard G. De Jong WH, et al. Among authors: geertsma re. Drug Deliv Transl Res. 2022 Sep;12(9):2042-2047. doi: 10.1007/s13346-022-01208-4. Epub 2022 Jul 30. Drug Deliv Transl Res. 2022. PMID: 35908133 Free PMC article.

5

Analysis of the occupational, consumer and environmental exposure to engineered nanomaterials used in 10 technology sectors.

Nowack B, Brouwer C, Geertsma RE, Heugens EH, Ross BL, Toufektsian MC, Wijnhoven SW, Aitken RJ. Nowack B, et al. Nanotoxicology. 2013 Sep;7(6):1152-6. doi: 10.3109/17435390.2012.711863. Epub 2012 Aug 21. Nanotoxicology. 2013. PMID: 22783888

6

Considerations on the EU definition of a nanomaterial: science to support policy making.

Bleeker EA, de Jong WH, Geertsma RE, Groenewold M, Heugens EH, Koers-Jacquemijns M, van de Meent D, Popma JR, Rietveld AG, Wijnhoven SW, Cassee FR, Oomen AG. Bleeker EA, et al. Among authors: geertsma re. Regul Toxicol Pharmacol. 2013 Feb;65(1):119-25. doi: 10.1016/j.yrtph.2012.11.007. Epub 2012 Nov 29. Regul Toxicol Pharmacol. 2013. PMID: 23200793

7

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.

Giannakou C, Park MV, de Jong WH, van Loveren H, Vandebriel RJ, Geertsma RE. Giannakou C, et al. Int J Nanomedicine. 2016 Jun 22;11:2935-52. doi: 10.2147/IJN.S102385. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27382281 Free PMC article. Review.

8

Study to determine the presence of antipolymer antibodies in a group of Dutch women with a silicone breast implant.

De Jong WH, Goldhoorn CA, Kallewaard M, Geertsma RE, Van Loveren H, Bijlsma JW, Schouten JS. De Jong WH, et al. Among authors: geertsma re. Clin Exp Rheumatol. 2002 Mar-Apr;20(2):151-60. Clin Exp Rheumatol. 2002. PMID: 12051393

9

Medical devices manufactured from latex: European regulatory initiatives.

De Jong WH, Geertsma RE, Tinkler JJ. De Jong WH, et al. Among authors: geertsma re. Methods. 2002 May;27(1):93-8. doi: 10.1016/S1046-2023(02)00057-9. Methods. 2002. PMID: 12079423 Review.

10

The kinetics of the tissue distribution of silver nanoparticles of different sizes.

Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, Van Eijkeren JC, Geertsma RE, De Jong WH. Lankveld DP, et al. Among authors: geertsma re. Biomaterials. 2010 Nov;31(32):8350-61. doi: 10.1016/j.biomaterials.2010.07.045. Epub 2010 Aug 4. Biomaterials. 2010. PMID: 20684985

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page